Reduced Ischemic Lesion Growth with Heparin in Acute Ischemic Stroke

被引:7
作者
Rocha, Eva A. [1 ,2 ]
Ji, Ruijun [1 ,3 ]
Ay, Hakan [1 ,4 ]
Li, Zixiao [1 ,3 ]
Murat, Ethem [5 ]
Silva, Gisele S. [6 ]
Sorensen, Alma Gregory [7 ]
Wu, Ona [1 ]
Singhal, Aneesh B. [1 ,2 ]
机构
[1] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA
[2] Univ Fed Sao Paulo, Dept Neurol, Sao Paulo, SP, Brazil
[3] Capital Med Univ, Beijing Tiantan Hosp, Dept Neurol, Beijing, Peoples R China
[4] Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA USA
[5] Hacettepe Univ, Dept Neurol, Ankara, Turkey
[6] Hosp Israelita Albert Einstein, Sao Paulo, SP, Brazil
[7] IMRIS, Minnetonka, MN USA
关键词
Heparin; anticoagulation; neuroprotection; acute stroke; diffusion-weighted MRI; perfusion-weighted MRI; ischemic lesion growth; MOLECULAR-WEIGHT HEPARIN; MAGNETIC-RESONANCE; ATRIAL-FIBRILLATION; CEREBRAL-ISCHEMIA; INFARCT GROWTH; SELECTION; ENOXAPARIN; MANAGEMENT; ALTEPLASE; ASPIRIN;
D O I
10.1016/j.jstrokecerebrovasdis.2019.03.016
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Objective: The role of heparin in acute ischemic stroke is controversial. We investigated the effect of heparin on ischemic lesion growth. Methods: Data were analyzed on nonthrombolyzed ischemic stroke patients in whom diffusion-weighted imaging (DWI)/perfusion-weighted imaging (PWI) MRI was performed less than 12 hours of last known well and showed a PWI-DWI lesion mismatch, and who underwent follow-up neuroimaging at least 4 days after admission. Lesion growth was assessed by (1) absolute lesion growth and (2) percentage mismatch lost (PML). Univariate and multivariate regression analysis, and propensity score matching, were used to determine the effects of heparin on ischemic lesion growth. Results: Of the 113 patients meeting study criteria, 59 received heparin within 24 hours. Heparin use was associated with similar to 5-fold reductions in PML (3.5% versus 19.2%, P=.002) and absolute lesion growth (4.7 versus 20.5 mL, P=.009). In multivariate regression models, heparin independently predicted reduced PML (P=.04) and absolute lesion growth (P=.04) in the entire cohort, and in multiple subgroups (patients with and without proximal artery occlusion; DWI volume greater than 5 mL; cardio-embolic mechanism; DEFUSE-3 target mismatch). In propensity score matching analysis where patients were matched by admission NIHSS, DWI volume and proximal artery occlusion, heparin remained an independent predictor of PML (P=.048) and tended to predict absolute lesion growth (P=.06). Heparin treatment did not predict functional outcome at discharge or 90 days. Conclusion: Early heparin treatment in acute ischemic stroke patients with PWI-DWI mismatch attenuates ischemic lesion growth. Clinical trials with careful patient selection are warranted to investigate the potential ischemic protective effects of heparin.
引用
收藏
页码:1500 / 1508
页数:9
相关论文
共 43 条
  • [11] Heparin in acute stroke with atrial fibrillation -: Clinical relevance of very early treatment
    Chamorro, A
    Vila, N
    Ascaso, C
    Blanc, R
    [J]. ARCHIVES OF NEUROLOGY, 1999, 56 (09) : 1098 - 1102
  • [12] Comparison of the acute-phase response in patients with ischemic stroke treated with high-dose heparin or aspirin
    Chamorro, A
    Obach, V
    Vila, N
    Revilla, M
    Cervera, A
    Ascaso, C
    [J]. JOURNAL OF THE NEUROLOGICAL SCIENCES, 2000, 178 (01) : 17 - 22
  • [13] Endovascular vs medical management of acute ischemic stroke
    Chen, Ching-Jen
    Ding, Dale
    Starke, Robert M.
    Mehndiratta, Prachi
    Crowley, R. Webster
    Liu, Kenneth C.
    Southerland, Andrew M.
    Worrall, Bradford B.
    [J]. NEUROLOGY, 2015, 85 (22) : 1980 - 1990
  • [14] Effects of alteplase beyond 3 h after stroke in the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET): a placebo-controlled randomised trial
    Davis, Stephen M.
    Donnan, Geoffrey A.
    Parsons, Mark W.
    Levi, Christopher
    Butcher, Kenneth S.
    Peeters, Andre
    Barber, P. Alan
    Bladin, Christopher
    De Silva, Deidre A.
    Byrnes, Graham
    Chalk, Jonathan B.
    Fink, John N.
    Kimber, Thomas E.
    Schultz, David
    Hand, Peter J.
    Frayne, Judith
    Hankey, Graeme
    Muir, Keith
    Gerraty, Richard
    Tress, Brian M.
    Desmond, Patricia M.
    [J]. LANCET NEUROLOGY, 2008, 7 (04) : 299 - 309
  • [15] Exacerbation of Thromboinflammation by Hyperglycemia Precipitates Cerebral Infarct Growth and Hemorrhagic Transformation
    Desilles, Jean-Philippe
    Syvannarath, Varouna
    Ollivier, Veronique
    Journe, Clement
    Delbosc, Sandrine
    Ducroux, Celina
    Boisseau, William
    Louedec, Liliane
    Di Meglio, Lucas
    Loyau, Stephane
    Jandrot-Perrus, Martine
    Potier, Louis
    Michel, Jean-Baptiste
    Mazighi, Mikael
    Ho-Tin-Noe, Benoit
    [J]. STROKE, 2017, 48 (07) : 1932 - +
  • [16] Proof-of-principle phase II MRI studies in stroke -: Sample size estimates from dichotomous and continuous data
    Donnan, Geoffrey A.
    Davis, Stephen M.
    Phan, Thanh G.
    Ludbrook, John
    Byrnes, Graham
    Parsons, Mark
    Barber, Alan P.
    Reutens, David C.
    Rose, Stephen E.
    Chalk, Jonathan
    Demchuk, Andrew M.
    Coutts, Shelagh B.
    Simon, Jessica E.
    Tomanek, Anna
    Roether, Joachim
    Weiller, Comelius
    Fiehler, Jens
    Thomalla, Gotz
    Kucinski, Thomas
    Schellinger, Peter D.
    Hacke, Werner
    Gass, Achim
    Szabo, Kristina
    Hennerici, Michael
    Siebler, Mario
    Villringer, Arno
    Junge-Huelsing, G. J.
    Pedraza, Salvador
    Davalos, Antoni
    Castillo, Jose
    Albers, Gregory W.
    Lansberg, Maarten G.
    Thijs, Vincent N.
    Bammer, Roland
    Moseley, Michael E.
    Marks, Michael
    Warach, Steve
    Baird, Alison
    Kidwell, Chelsea
    Saver, Jeff
    Sorensen, Greg
    Fisher, Marc
    Nighoghossian, Norbert
    Muir, Keith
    [J]. STROKE, 2006, 37 (10) : 2521 - 2525
  • [17] Penumbral selection of patients for trials of acute stroke therapy
    Donnan, Geoffrey A.
    Baron, Jean-Claude
    Ma, Henry
    Davis, Stephen M.
    [J]. LANCET NEUROLOGY, 2009, 8 (03) : 261 - 269
  • [18] ERDI A, 1976, LANCET, V2, P342
  • [19] THE USE OF ANTICOAGULANTS IN CEREBRAL THROMBOSIS
    FISHER, CM
    [J]. NEUROLOGY, 1958, 8 (05) : 311 - 332